Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 22072743)

1.

BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein.

Chiappetta G, Basile A, Arra C, Califano D, Pasquinelli R, Barbieri A, De Simone V, Rea D, Giudice A, Pezzullo L, De Laurenzi V, Botti G, Losito S, Conforti D, Turco MC.

J Clin Endocrinol Metab. 2012 Jan;97(1):E115-20. doi: 10.1210/jc.2011-0484. Epub 2011 Nov 9.

PMID:
22072743
2.

The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Chiappetta G, Ammirante M, Basile A, Rosati A, Festa M, Monaco M, Vuttariello E, Pasquinelli R, Arra C, Zerilli M, Todaro M, Stassi G, Pezzullo L, Gentilella A, Tosco A, Pascale M, Marzullo L, Belisario MA, Turco MC, Leone A.

J Clin Endocrinol Metab. 2007 Mar;92(3):1159-63. Epub 2006 Dec 12.

PMID:
17164298
3.

Proteasome inhibitor MG132 induces BAG3 expression through activation of heat shock factor 1.

Du ZX, Zhang HY, Meng X, Gao YY, Zou RL, Liu BQ, Guan Y, Wang HQ.

J Cell Physiol. 2009 Mar;218(3):631-7. doi: 10.1002/jcp.21634.

PMID:
19006120
4.

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S.

Oncologist. 2011;16(3):296-309. doi: 10.1634/theoncologist.2010-0317. Epub 2011 Feb 25.

5.

Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.

J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295. Epub 2012 Oct 10.

6.

IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth.

Ammirante M, Rosati A, Arra C, Basile A, Falco A, Festa M, Pascale M, d'Avenia M, Marzullo L, Belisario MA, De Marco M, Barbieri A, Giudice A, Chiappetta G, Vuttariello E, Monaco M, Bonelli P, Salvatore G, Di Benedetto M, Deshmane SL, Khalili K, Turco MC, Leone A.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7497-502. doi: 10.1073/pnas.0907696107. Epub 2010 Apr 5.

7.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

8.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86. Epub 2010 May 14.

9.

Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells.

Du ZX, Meng X, Zhang HY, Guan Y, Wang HQ.

Biochem Biophys Res Commun. 2008 May 9;369(3):894-8. doi: 10.1016/j.bbrc.2008.02.112. Epub 2008 Mar 4.

PMID:
18325327
10.

The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome.

Virador VM, Davidson B, Czechowicz J, Mai A, Kassis J, Kohn EC.

PLoS One. 2009;4(4):e5136. doi: 10.1371/journal.pone.0005136. Epub 2009 Apr 8.

11.
12.

Bcl2-associated athanogene 3 interactome analysis reveals a new role in modulating proteasome activity.

Chen Y, Yang LN, Cheng L, Tu S, Guo SJ, Le HY, Xiong Q, Mo R, Li CY, Jeong JS, Jiang L, Blackshaw S, Bi LJ, Zhu H, Tao SC, Ge F.

Mol Cell Proteomics. 2013 Oct;12(10):2804-19. doi: 10.1074/mcp.M112.025882. Epub 2013 Jul 3.

13.

Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.

Kim SH, Shin HY, Kim YS, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.

Anticancer Res. 2014 Sep;34(9):4857-68.

PMID:
25202067
14.

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD.

J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8. Epub 2007 Sep 18.

PMID:
17878251
15.

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE.

J Clin Invest. 2005 Jan;115(1):94-101.

16.

BRAF is a therapeutic target in aggressive thyroid carcinoma.

Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.

Clin Cancer Res. 2006 Mar 1;12(5):1623-9.

17.

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.

Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C.

Mol Cancer Res. 2008 May;6(5):751-9. doi: 10.1158/1541-7786.MCR-07-2001. Epub 2008 May 5.

18.

Knockdown of PRAS40 inhibits insulin action via proteasome-mediated degradation of IRS1 in primary human skeletal muscle cells.

Wiza C, Herzfeld de Wiza D, Nascimento EB, Lehr S, Al-Hasani H, Ouwens DM.

Diabetologia. 2013 May;56(5):1118-28. doi: 10.1007/s00125-013-2861-9. Epub 2013 Mar 5.

PMID:
23460019
19.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

20.

Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo.

Yu XM, Phan T, Patel PN, Jaskula-Sztul R, Chen H.

Cancer. 2013 Feb 15;119(4):774-81. doi: 10.1002/cncr.27742. Epub 2012 Sep 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk